The in vivo efficacy was accompanied by a significant decrease in the prometastatic factors cathepsin B (CtsB), cathepsin S (CtsS), FoxC2, MMP‐2, MMP‐3, MMP‐8, ADAM8, and ADAMP9, all of which are peritumoral proteolytic factors known to drive angiogenesis, migration, invasion, and metastasis.28, 29, 30, 31 A decrease in CCL7 and CCL8 levels upon RANCE‐1 treatment was also observed, which could decrease the tumor's ability to recruit monocytes, thus rendering the tumor ecosystem more hostile to tumor progression. This evidence concerns the gene FOXC2 and neoplasm.